{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:28:23Z","timestamp":1793039303672,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jaip.2022.12.012","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T19:50:04Z","timestamp":1672084204000},"page":"896-905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"11","author":[{"given":"Meiling","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo A.","family":"Douglass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawomir","family":"Lazarewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Jaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.12.012_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.582964","article-title":"Current approach in the diagnosis and management of allergic bronchopulmonary aspergillosis in children with cystic fibrosis","volume":"8","author":"Sunman","year":"2020","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaip.2022.12.012_bib2","series-title":"Allergic bronchopulmonary aspergillosis. Treasure Island (Fla)","author":"Jack","year":"2022"},{"key":"10.1016\/j.jaip.2022.12.012_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1183\/09059180.00007413","article-title":"Allergic aspergillosis of the respiratory tract","volume":"23","author":"Shah","year":"2014","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2022.12.012_bib4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/antibiotics10040357","article-title":"Allergic diseases caused by Aspergillus species in patients with cystic fibrosis","volume":"10","author":"Curran","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jaip.2022.12.012_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4103\/ijmr.IJMR_1187_19","article-title":"Allergic bronchopulmonary aspergillosis","volume":"151","author":"Agarwal","year":"2020","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jaip.2022.12.012_bib6","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/cea.12595","article-title":"Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis","volume":"45","author":"Maturu","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.12.012_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/1744666X.2017.1232620","article-title":"Allergic bronchopulmonary aspergillosis in asthma","volume":"13","author":"Knutsen","year":"2017","journal-title":"Exp Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2022.12.012_bib8","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1016\/j.jaip.2020.05.055","article-title":"Omalizumab is an effective intervention in severe asthma with fungal sensitization","volume":"8","author":"Wark","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.12.012_bib9","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/ppul.24465","article-title":"An investigation into biomarkers for the diagnosis of ABPA and aspergillus disease in cystic fibrosis","volume":"54","author":"Keown","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"suppl 3","key":"10.1016\/j.jaip.2022.12.012_bib10","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1086\/376525","article-title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference","volume":"37","author":"Stevens","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2022.12.012_bib11","first-page":"e4538","article-title":"Treating allergic bronchopulmonary aspergillosis: a review","volume":"11","author":"Patel","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2022.12.012_bib12","first-page":"17","article-title":"Allergic bronchopulmonary aspergillosis","volume":"2","author":"Tracy","year":"2016","journal-title":"J\u00a0Fungi (Basel)"},{"key":"10.1016\/j.jaip.2022.12.012_bib13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1159\/000507216","article-title":"Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis complicated by chronic bacterial infection in the airways","volume":"181","author":"Tomomatsu","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2022.12.012_bib14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","article-title":"Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis","volume":"3","author":"Voskamp","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.12.012_bib15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2022.12.012_bib16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-86-4-405","article-title":"Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis","volume":"86","author":"Rosenberg","year":"1977","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2022.12.012_bib18","unstructured":"Genentech Inc. Xolair (omalizumab) injection. Prescribing information. Accessed June 7, 2022. https:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf"},{"key":"10.1016\/j.jaip.2022.12.012_bib19","unstructured":"Genentech Inc. Xolair (omalizumab). Data on file. Safety update. Period covered: January 29, 2018 to March 28, 2022. Issued May 19, 2022. Accessed\u00a0January 14, 2023. https:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf"},{"key":"10.1016\/j.jaip.2022.12.012_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2019.07.011","article-title":"Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis","volume":"19","author":"Koutsokera","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.jaip.2022.12.012_bib21","unstructured":"Novartis. An exploratory study to assess multiple doses of Omalizumab in patients with cystic fibrosis complicated by acute bronchopulmonary aspergillosis (ABPA). ClinicalTrials.gov Identifier: NCT00787917. CRS: 5500100000010742; 2008. Accessed June 7, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00787917"},{"key":"10.1016\/j.jaip.2022.12.012_bib22","first-page":"CD010288","article-title":"Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","volume":"9","author":"Jat","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2022.12.012_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rmed.2016.11.019","article-title":"Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: a synthesis review of published literature","volume":"122","author":"Li","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2022.12.012_bib24","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jaip.2019.01.056","article-title":"Successful treatment with omalizumab of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: case reports and literature review","volume":"7","author":"Parisi","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.12.012_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.jaip.2022.12.012_bib27","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2022.12.012_bib28","series-title":"Development of a quality appraisal tool for case series studies using a modified Delphi technique","author":"Moga","year":"2012"},{"key":"10.1016\/j.jaip.2022.12.012_bib29","unstructured":"Joanna Briggs Institute. Critical appraisal tools for use in JBI Systematic Reviews: Checklist for case reports. Accessed June 7, 2022. https:\/\/jbi.global\/critical-appraisal-tools"},{"key":"10.1016\/j.jaip.2022.12.012_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaip.2022.12.012_bib31","first-page":"304","article-title":"Allergic bronchopulmonary aspergillosis treated successfully with omalizumab","volume":"23","author":"Aguiar","year":"2017","journal-title":"Rev Port Pneumol (2006)"},{"key":"10.1016\/j.jaip.2022.12.012_bib32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2500\/ar.2015.6.0128","article-title":"Steroid sparing effect of omalizumab in seropositive allergic bronchopulmonary aspergillosis","volume":"6","author":"Beam","year":"2015","journal-title":"Allergy Rhinol (Providence)"},{"key":"10.1016\/j.jaip.2022.12.012_bib33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18176\/jiaci.0564","article-title":"Successful treatment of allergic bronchopulmonary aspergillosis with benralizumab in a patient who did not respond to omalizumab","volume":"30","author":"Bernal-Rubio","year":"2020","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2022.12.012_bib34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1398-9995.2009.02147.x","article-title":"Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis","volume":"65","author":"Brinkmann","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.12.012_bib35","first-page":"439","article-title":"Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis","volume":"44","author":"Cunha","year":"2018","journal-title":"J\u00a0Bras Pneumol"},{"key":"10.1016\/j.jaip.2022.12.012_bib36","first-page":"88","article-title":"Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin E therapy (omalizumab)","volume":"17","author":"ElMallah","year":"2012","journal-title":"J\u00a0Pediatr Pharmacol Ther"},{"key":"10.1016\/j.jaip.2022.12.012_bib37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.anai.2015.06.014","article-title":"Omalizumab, an additional therapy for allergic bronchopulmonary aspergillosis","volume":"115","author":"Evans","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.12.012_bib38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jmii.2013.10.003","article-title":"Anti-IgE therapy for allergic bronchopulmonary aspergillosis","volume":"49","author":"Homma","year":"2016","journal-title":"J\u00a0Microbiol Immunol Infect"},{"key":"10.1016\/j.jaip.2022.12.012_bib39","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ppul.20907","article-title":"Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab)","volume":"43","author":"Kanu","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2022.12.012_bib40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4103\/INJMS.INJMS_149_19","article-title":"Steroid-sparing effect of omalizumab in stage IV (corticosteroid dependent) allergic bronchopulmonary aspergillosis","volume":"11","author":"Kathuria","year":"2020","journal-title":"India J Med Specialities"},{"key":"10.1016\/j.jaip.2022.12.012_bib41","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jaip.2015.11.014","article-title":"Following total IgE concentration in patients with allergic bronchopulmonary aspergillosis on omalizumab","volume":"4","author":"Kelso","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.12.012_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.07.2008.0379","article-title":"Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"2009","author":"Lebecque","year":"2009","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaip.2022.12.012_bib43","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3109\/02770903.2010.491144","article-title":"Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab","volume":"47","author":"Lin","year":"2010","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2022.12.012_bib44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.anai.2010.10.022","article-title":"Codiagnosis of allergic bronchopulmonary aspergillosis and sarcoid in a severe asthmatic patient","volume":"105","author":"McVay","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.12.012_bib45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13223-020-00454-w","article-title":"Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?","volume":"16","author":"Mummler","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2022.12.012_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-006918","article-title":"A\u00a0rare CFTR intronic mutation related to a mild CF disease in a 12-year-old girl","volume":"2012","author":"Nathan","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaip.2022.12.012_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.arbres.2008.05.007","article-title":"Effective anti-immunoglobulin-E antibody treatment of a patient with allergic bronchopulmonary aspergillosis [in Spanish]","volume":"45","author":"Quint\u00e1s V\u00e1zquez","year":"2009","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.jaip.2022.12.012_bib48","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/02770900902849871","article-title":"Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach","volume":"46","author":"Randhawa","year":"2009","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2022.12.012_bib49","first-page":"133","article-title":"A\u00a0Case of Allergic bronchopulmonary aspergillosis treated with omalizumab","volume":"22","author":"Sastre","year":"2012","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2022.12.012_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rmedc.2009.12.004","article-title":"Allergic bronchopulmonary aspergillosis (ABPA) an IgE mediated disease?","volume":"4","author":"Schulze","year":"2011","journal-title":"Respir Med CME"},{"issue":"suppl 1","key":"10.1016\/j.jaip.2022.12.012_bib51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1258\/jrsm.2009.s19011","article-title":"Life-threatening allergic bronchopulmonary aspergillosis treated with methylprednisolone and anti-IgE monoclonal antibody","volume":"102","author":"Thomas","year":"2009","journal-title":"J\u00a0R Soc Med"},{"key":"10.1016\/j.jaip.2022.12.012_bib52","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/thx.2004.035519","article-title":"Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody","volume":"62","author":"van der Ent","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2022.12.012_bib53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jaip.2013.08.014","article-title":"Unexpected decrease in total IgE in a patient with allergic bronchopulmonary aspergillosis treated with omalizumab","volume":"2","author":"Wolf","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.12.012_bib54","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.prrv.2012.11.004","article-title":"Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis","volume":"14","author":"Wong","year":"2013","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jaip.2022.12.012_bib55","first-page":"1839","article-title":"Anti IgE antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis","volume":"18","author":"Zicari","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jaip.2022.12.012_bib56","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ppul.20804","article-title":"Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis","volume":"43","author":"Zirbes","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2022.12.012_bib57","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaip.2015.10.020","article-title":"Measuring total IgE is useful in detecting exacerbations in patients with allergic bronchopulmonary aspergillosis receiving omalizumab","volume":"4","author":"Bobolea","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"suppl 64","key":"10.1016\/j.jaip.2022.12.012_bib58","first-page":"2223","article-title":"ABPA relapse after discontinuation of omalizumab","volume":"56","author":"Bucca","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2022.12.012_bib59","first-page":"190","article-title":"Role of omalizumab in the management of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis [in Spanish]","volume":"144","author":"Pecell\u00edn","year":"2015","journal-title":"Med Clin (Barc)"},{"issue":"suppl 2","key":"10.1016\/j.jaip.2022.12.012_bib60","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1093\/mmy\/myy063","article-title":"Challenging cases in fungal asthma","volume":"57","author":"Agarwal","year":"2019","journal-title":"Med Mycol"},{"key":"10.1016\/j.jaip.2022.12.012_bib61","first-page":"A3032","article-title":"Efficacy and safety of omalizumab in severe allergic asthma and allergic comorbidities: a single-center, real-life experience in China. ATS 2020","volume":"2012","author":"Zhao","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.12.012_bib62","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/JAA.S156049","article-title":"Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"11","author":"Ashkenazi","year":"2018","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2022.12.012_bib63","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2500\/aap.2015.36.3909","article-title":"Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: one center's experience with 14 cases","volume":"36","author":"Aydin","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2022.12.012_bib64","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/JAA.S34579","article-title":"Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab","volume":"5","author":"Collins","year":"2012","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2022.12.012_bib65","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/qjmed\/hcw027","article-title":"Qualitative effects of omalizumab on concomitant IgE-mediated disease in a severe asthmatic population: a real life observational study","volume":"109","author":"Cusack","year":"2016","journal-title":"QJM"},{"key":"10.1016\/j.jaip.2022.12.012_bib66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1753465814547517","article-title":"Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"8","author":"Lehmann","year":"2014","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaip.2022.12.012_bib67","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ppul.23612","article-title":"Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients","volume":"52","author":"Nove-Josserand","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2022.12.012_bib68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.rmed.2017.11.007","article-title":"Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis","volume":"133","author":"Perisson","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2022.12.012_bib69","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21911\/aai.476","article-title":"Allergic bronchopulmonary aspergillosis: a clinical evaluation of 15 patients and successful omalizumab treatment of five patients","volume":"17","author":"\u00dcnal","year":"2019","journal-title":"Asthma Allergy Immunol"},{"key":"10.1016\/j.jaip.2022.12.012_bib70","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.reval.2018.12.003","article-title":"Effet de l\u2019omalizumab dans l\u2019aspergillose broncho-pulmonaire allergique: \u00e0 propos de 10 patients asthmatiques [in French]","volume":"59","author":"Melscoet","year":"2019","journal-title":"Rev Fr Allergol"},{"key":"10.1016\/j.jaip.2022.12.012_bib71","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1398-9995.2011.02599.x","article-title":"Allergic bronchopulmonary aspergillosis and omalizumab","volume":"66","author":"Tillie-Leblond","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.12.012_bib72","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1060028015624204","article-title":"Omalizumab treatment for allergic bronchopulmonary aspergillosis in cystic fibrosis","volume":"50","author":"Emiralioglu","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaip.2022.12.012_bib73","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/thx.2010.153312","article-title":"Effects of omalizumab in aspergillus-associated airway disease","volume":"66","author":"P\u00e9rez-de-Llano","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2022.12.012_bib74","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/atm.ATM_231_16","article-title":"Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"12","author":"Janahi","year":"2017","journal-title":"Ann Thorac Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822013253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822013253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:37:41Z","timestamp":1761975461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822013253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2213219822013253"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.12.012","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}